To enhance immunotherapy efficacy, clinical trials have investigated combining anti-PD-1/PD-L1 antibodies with anti-CTLA-4 antibodies or TKIs as first-line RCC treatments, demonstrating superior outcomes to TKI monotherapy (44). The gene discussed is CTLA4; the disease is renal cell carcinoma.